B-cell malignancies: capture-sequencing strategies for identification of gene rearrangements and translocations into immunoglobulin gene loci

References

• Delves PJ, Roitt IM. The immune system. First of two parts. N Engl J Med. 2000;343(1):37–49.
   PubMed Web of Science ®Google Scholar
• Nishana M, Raghavan SC. Role of recombination activating genes in the generation of antigen receptor diversity and beyond. Immunology. 2012;137(4):271–281.
   Web of Science ®Google Scholar
• Vuong BQ, Herrick-Reynolds K, Vaidyanathan B, et al. A DNA break- and phosphorylation-dependent positive feedback loop promotes immunoglobulin class-switch recombination. Nat Immunol. 2013;14(11):1183–1189.
   PubMed Web of Science ®Google Scholar
• Victor KD, Capra JD. An apparently common mechanism of generating antibody diversity: length variation of the VL-JL junction. Mol Immunol. 1994;31(1):39–46.
   Web of Science ®Google Scholar
• Jung D, Giallourakis C, Mostoslavsky R, Alt FW. Mechanism and control of V(D)J recombination at the immunoglobulin heavy chain locus. Annu Rev Immunol. 2006;24:541–570.
   PubMed Web of Science ®Google Scholar
• Xu Z, Zan H, Pone EJ, Mai T, Casali P. Immunoglobulin class-switch DNA recombination: induction, targeting and beyond. Nat Rev Immunol. 2012;12(7):517–531.
   PubMed Web of Science ®Google Scholar
• Roy AL, Sen R, Roeder RG. Enhancer-promoter communication and transcriptional regulation of IgH. Trends Immunol. 2011;32(11):532–539.
   PubMed Web of Science ®Google Scholar
• Victor KD, Vu K, Feeney AJ. Limited junctional diversity in kappa light chains. Junctional sequences from CD43+B220+ early B cell progenitors resemble those from peripheral B cells. J Immunol. 1994;152(7):3467–3475.
   Web of Science ®Google Scholar
• Langerak AW, van Dongen JJM. Recombination in the human IGK locus. Crit Rev Immunol. 2006;26(1):23–42.
   Web of Science ®Google Scholar
• Langerak AW, Nadel B, de Torbal A, et al. Unraveling the consecutive recombination events in the human IGK locus. J Immunol. 2004;173(6):3878–3888.
   Web of Science ®Google Scholar
• Nutt SL, Taubenheim N, Hasbold J, Corcoran LM, Hodgkin PD. The genetic network controlling plasma cell differentiation. Semin Immunol. 2011;23(5):341–349.
   PubMed Web of Science ®Google Scholar
• Fraenkel S, Mostoslavsky R, Novobrantseva TI, et al. Allelic ‘choice’ governs somatic hypermutation in vivo at the immunoglobulin kappa-chain locus. Nat Immunol. 2007;8(7):715–722.
   Web of Science ®Google Scholar
• Stavnezer J, Guikema JEJ, Schrader CE. Mechanism and regulation of class switch recombination. Annu Rev Immunol. 2008;26:261–292.
   PubMed Web of Science ®Google Scholar
• Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell. 2000;102(5):553–563.
   PubMed Web of Science ®Google Scholar
• Chaudhuri J, Tian M, Khuong C, Chua K, Pinaud E, Alt FW. Transcription-targeted DNA deamination by the AID antibody diversification enzyme. Nature. 2003;422(6933):726–730.
   PubMed Web of Science ®Google Scholar
• Ramiro AR, Stavropoulos P, Jankovic M, Nussenzweig MC. Transcription enhances AID-mediated cytidine deamination by exposing single-stranded DNA on the nontemplate strand. Nat Immunol. 2003;4(5):452–456.
   PubMed Web of Science ®Google Scholar
• Keim C, Kazadi D, Rothschild G, Basu U. Regulation of AID, the B-cell genome mutator. Genes Dev. 2013;27(1):1–17.
   Web of Science ®Google Scholar
• Shapiro-Shelef M, Calame K. Regulation of plasma-cell development. Nat Rev Immunol. 2005;5(3):230–242.
   Web of Science ®Google Scholar
• Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med. 2010;362(15):1417–1429.
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, Nov 1997. Ann Oncol. 1999;10(12):1419–1432.
   PubMed Web of Science ®Google Scholar
• Cleary ML, Chao J, Warnke R, Sklar J. Immunoglobulin gene rearrangement as a diagnostic criterion of B-cell lymphoma. Proc Natl Acad Sci U S A. 1984;81(2):593–597.
   PubMed Web of Science ®Google Scholar
• Aubin J, Davi F, Nguyen-Salomon F, et al. Description of a novel FR1 IgH PCR strategy and its comparison with three other strategies for the detection of clonality in B cell malignancies. Leukemia. 1995;9(3):471–479.
   Web of Science ®Google Scholar
• Lovén J, Hoke HA, Lin CY, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013;153(2):320–334.
   PubMed Web of Science ®Google Scholar
• Tsai AG, Lieber MR. Mechanisms of chromosomal rearrangement in the human genome. BMC Genomics. 2010;11 Suppl 1:S1.
   Google Scholar
• Huret J. Atlas of Genetics and Cytogenetics in Oncology and Haematology. Cancer Net Cytogenet. Available from: http://atlasgeneticsoncology.org/. Accessed September 1, 2014.
   Google Scholar
• Boyd KD, Ross FM, Chiecchio L, et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia. 2012;26(2):349–355.
   PubMed Web of Science ®Google Scholar
• Robinson HM, Taylor KE, Jalali GR, Cheung KL, Harrison CJ, Moorman AV. t(14;19)(q32;q13): a recurrent translocation in B-cell precursor acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2004;39(1):88–92.
   Web of Science ®Google Scholar
• Chapiro E, Radford-Weiss I, Cung HA, et al. Chromosomal translocations involving the IGH@ locus in B-cell precursor acute lymphoblastic leukemia: 29 new cases and a review of the literature. Cancer Genet. 2013;206(5):162–173.
   Web of Science ®Google Scholar
• Akasaka T, Balasas T, Russell LJ, et al. Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood. 2007;109(8):3451–3461.
   Web of Science ®Google Scholar
• Russell LJ, Akasaka T, Majid A, et al. t(6;14)(p22;q32): a new recurrent IGH@ translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood. 2008;111(1):387–391.
   Web of Science ®Google Scholar
• Russell LJ, De Castro DG, Griffiths M, et al. A novel translocation, t(14;19)(q32;p13), involving IGH@ and the cytokine receptor for erythropoietin. Leukemia. 2009;23(3):614–617.
   Web of Science ®Google Scholar
• Dyer MJS, Akasaka T, Capasso M, et al. Immunoglobulin heavy chain locus chromosomal translocations in B-cell precursor acute lymphoblastic leukemia: rare clinical curios or potent genetic drivers? Blood. 2010;115(8):1490–1499.
   Web of Science ®Google Scholar
• Russell LJ, Enshaei A, Jones L, et al. IGH@ translocations are prevalent in teenagers and young adults with acute lymphoblastic leukemia and are associated with a poor outcome. J Clin Oncol. 2014;32(14):1453–1462.
   PubMed Web of Science ®Google Scholar
• Macintyre EA, d’Auriol L, Duparc N, Leverger G, Galibert F, Sigaux F. Use of oligonucleotide probes directed against T cell antigen receptor gamma delta variable-(diversity)-joining junctional sequences as a general method for detecting minimal residual disease in acute lymphoblastic leukemias. J Clin Invest. 1990;86(6):2125–2135.
   Web of Science ®Google Scholar
• Hansen-Hagge TE, Yokota S, Bartram CR. Detection of minimal residual disease in acute lymphoblastic leukemia by in vitro amplification of rearranged T-cell receptor delta chain sequences. Blood. 1989;74(5):1762–1767.
   Web of Science ®Google Scholar
• Agsalda M, Kusao I, Troelstrup D, Shiramizu B. Screening for residual disease in pediatric Burkitt lymphoma using consensus primer pools. Adv Hematol. 2009;2009:412163.
   Google Scholar
• Jares P, Campo E. Advances in the understanding of mantle cell lymphoma. Br J Haematol. 2008;142(2):149–165.
   PubMed Web of Science ®Google Scholar
• Orchard J, Garand R, Davis Z, et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood. 2003;101(12):4975–4981.
   PubMed Web of Science ®Google Scholar
• Royo C, Navarro A, Clot G, et al. Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease. Leukemia. 2012;26(8):1895–1898.
   PubMed Web of Science ®Google Scholar
• Del Giudice I, Messina M, Chiaretti S, et al. Behind the scenes of non-nodal MCL: downmodulation of genes involved in actin cytoskeleton organization, cell projection, cell adhesion, tumour invasion, TP53 pathway and mutated status of immunoglobulin heavy chain genes. Br J Haematol. 2012;156(5):601–611.
   Web of Science ®Google Scholar
• Michaux L, Mecucci C, Stul M, et al. BCL3 rearrangement and t(14;19)(q32;q13) in lymphoproliferative disorders. Genes Chromosomes Cancer. 1996;15(1):38–47.
   Web of Science ®Google Scholar
• Ritgen M, Lange A, Stilgenbauer S, et al. Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood. 2003;101(5):2049–2053.
   Web of Science ®Google Scholar
• Stilgenbauer S, Bullinger L, Lichter P, Döhner H; German CLL Study Group (GCLLSG). Chronic lymphocytic leukemia. Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia. 2002;16(6):993–1007.
   PubMed Web of Science ®Google Scholar
• Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–1916.
   PubMed Web of Science ®Google Scholar
• Weiss LM, Warnke RA, Sklar J, Cleary ML. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med. 1987;317(19):1185–1189.
   PubMed Web of Science ®Google Scholar
• Bahler DW, Levy R. Clonal evolution of a follicular lymphoma: evidence for antigen selection. Proc Natl Acad Sci U S A. 1992;89(15):6770–6774.
   Web of Science ®Google Scholar
• Pasqualucci L, Khiabanian H, Fangazio M, et al. Genetics of follicular lymphoma transformation. Cell Rep. 2014;6(1):130–140.
   PubMed Web of Science ®Google Scholar
• Lossos IS, Alizadeh AA, Eisen MB, et al. Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc Natl Acad Sci U S A. 2000;97(18):10209–10213.
   Web of Science ®Google Scholar
• Rosenwald A, Staudt LM. Clinical translation of gene expression profiling in lymphomas and leukemias. Semin Oncol. 2002;29(3):258–263.
   PubMed Web of Science ®Google Scholar
• Sagaert X, Tousseyn T. Marginal zone B-cell lymphomas. Discov Med. 2010;10(50):79–86.
   Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BGM, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–3420.
   PubMed Web of Science ®Google Scholar
• Walker BA, Wardell CP, Johnson DC, et al. Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood. 2013;121(17):3413–3419.
   PubMed Web of Science ®Google Scholar
• Wagner SD, Martinelli V, Luzzatto L. Similar patterns of V kappa gene usage but different degrees of somatic mutation in hairy cell leukemia, prolymphocytic leukemia, Waldenstrom’s macroglobulinemia, and myeloma. Blood. 1994;83(12):3647–3653.
   Web of Science ®Google Scholar
• González D, van der Burg M, García-Sanz R, et al. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood. 2007;110(9):3112–3121.
   Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Dupret C, Asnafi V, Leboeuf D, et al. IgH/TCR rearrangements are common in MLL translocated adult AML and suggest an early T/myeloid or B/myeloid maturation arrest, which correlates with the MLL partner. Leukemia. 2005;19(12):2337–2338.
   Web of Science ®Google Scholar
• Evans PA, Pott CH, Groenen PJ, et al. Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia. 2007;21(2):207–214.
   Web of Science ®Google Scholar
• Liu H, Bench AJ, Bacon CM, et al. A practical strategy for the routine use of BIOMED-2 PCR assays for detection of B- and T-cell clonality in diagnostic haematopathology. Br J Haematol. 2007;138(1):31–43.
   Web of Science ®Google Scholar
• Arnold A, Cossman J, Bakhshi A, Jaffe ES, Waldmann TA, Korsmeyer SJ. Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid neoplasms. N Engl J Med. 1983;309(26):1593–1599.
   PubMed Web of Science ®Google Scholar
• Payne K, Wright P, Grant JW, et al. BIOMED-2 PCR assays for IGK gene rearrangements are essential for B-cell clonality analysis in follicular lymphoma. Br J Haematol. 2011;155(1):84–92.
   Web of Science ®Google Scholar
• González D, González M, Balanzategui A, et al. Molecular characteristics and gene segment usage in IGH gene rearrangements in multiple myeloma. Haematologica. 2005;90(7):906–913.
   Web of Science ®Google Scholar
• Konoplev S, Lin P, Qiu X, Medeiros LJ, Yin CC. Clonal relationship of extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue involving different sites. Am J Clin Pathol. 2010;134(1):112–118.
   Web of Science ®Google Scholar
• Yoshinaga H, Ohashi K, Yamamoto K, et al. Clonal identification of Burkitt’s lymphoma arising from lymphocyte-predominant Hodgkin’s disease. Br J Haematol. 1996;95(2):380–382.
   Web of Science ®Google Scholar
• Au WY, Srivastava G, Wong KY, et al. Transformation of diffuse large B-cell lymphoma into pre-B acute lymphoblastic leukemia: clinicopathologic features and clonal relationship. Hum Pathol. 2004;35(7):900–903.
   Web of Science ®Google Scholar
• Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010;11(6):543–552.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Child JA, de Tute RM, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol. 2013;31(20):2540–2457.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Böttcher S, Letestu R, et al. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia. 2013;27(1):142–149.
   PubMed Web of Science ®Google Scholar
• Richardson SE, Khan I, Rawstron A, et al. Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia. Br J Haematol. 2013;160(5):640–648.
   Web of Science ®Google Scholar
• De Haas V, Verhagen OJ, von dem Borne AE, Kroes W, van den Berg H, van der Schoot CE. Quantification of minimal residual disease in children with oligoclonal B-precursor acute lymphoblastic leukemia indicates that the clones that grow out during relapse already have the slowest rate of reduction during induction therapy. Leukemia. 2001;15(1):134–140.
   Web of Science ®Google Scholar
• Chen JS, Coustan-Smith E, Suzuki T, et al. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. Blood. 2001;97(7):2115–2220.
   Web of Science ®Google Scholar
• Moreira I, Papaioannou M, Mortuza FY, et al. Heterogeneity of VH-JH gene rearrangement patterns: an insight into the biology of B cell precursor ALL. Leukemia. 2001;15(10):1527–1536.
   Web of Science ®Google Scholar
• Mortuza FY, Moreira IM, Papaioannou M, et al. Immunoglobulin heavy-chain gene rearrangement in adult acute lymphoblastic leukemia reveals preferential usage of J(H)-proximal variable gene segments. Blood. 2001;97(9):2716–2726.
   Web of Science ®Google Scholar
• Eckert C, von Stackelberg A, Seeger K, et al. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia – long-term results of trial ALL-REZ BFM P95/96. Eur J Cancer. 2013;49(6):1346–1355.
   PubMed Web of Science ®Google Scholar
• Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115(16):3206–3214.
   PubMed Web of Science ®Google Scholar
• Bassan R, Spinelli O, Oldani E, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009;113(18):4153–4162.
   PubMed Web of Science ®Google Scholar
• Spinelli O, Peruta B, Tosi M, et al. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica. 2007;92(5):612–618.
   PubMed Web of Science ®Google Scholar
• Thörn I, Forestier E, Botling J, et al. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry. Br J Haematol. 2011;152(6):743–753.
   Web of Science ®Google Scholar
• Lovisa F, Mussolin L, Corral L, et al. IGH and IGK gene rearrangements as PCR targets for pediatric Burkitt’s lymphoma and mature B-ALL MRD analysis. Lab Investig. 2009;89(10):1182–1186.
   Web of Science ®Google Scholar
• Gimenez E, Chauvet M, Rabin L, et al. Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d’Etude des Leucémies et Autres Maladies du Sang. Br J Haematol. 2012;158(2):186–197.
   PubMed Web of Science ®Google Scholar
• Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840–1847.
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Davis ZA, Oscier DG. Determination of how many immunoglobulin variable region heavy chain mutations are allowable in unmutated chronic lymphocytic leukaemia – long-term follow up of patients with different percentages of mutations. Br J Haematol. 2008;140(3):320–323.
   PubMed Web of Science ®Google Scholar
• Böttcher S, Stilgenbauer S, Busch R, et al. Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis. Leukemia. 2009;23(11):2007–2017.
   PubMed Web of Science ®Google Scholar
• Caspersson T, Zech L, Johansson C, Modest EJ. Identification of human chromosomes by DNA-binding fluorescent agents. Chromosoma. 1970;30(2):215–227.
   Web of Science ®Google Scholar
• Seabright M. A rapid banding technique for human chromosomes. Lancet. 1971;2(7731):971–972.
   PubMed Web of Science ®Google Scholar
• Kallioniemi A, Kallioniemi OP, Sudar D, et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science. 1992;258(5083):818–821.
   PubMed Web of Science ®Google Scholar
• Barrett MT, Scheffer A, Ben-Dor A, et al. Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA. Proc Natl Acad Sci U S A. 2004;101(51):17765–17770.
   PubMed Web of Science ®Google Scholar
• Jalali GR, Vorstman JAS, Errami A, et al. Detailed analysis of 22q11.2 with a high density MLPA probe set. Hum Mutat. 2008;29(3):433–440.
   Web of Science ®Google Scholar
• Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446(7137):758–764.
   PubMed Web of Science ®Google Scholar
• Walker BA, Wardell CP, Brioli A et al. Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients. Blood Cancer J. 2014;4:e191.
   PubMed Web of Science ®Google Scholar
• Bouamar H, Abbas S, Lin AP, et al. A capture-sequencing strategy identifies IRF8, EBF1, and APRIL as novel IGH fusion partners in B-cell lymphoma. Blood. 2013;122(5):726–733.
   PubMed Web of Science ®Google Scholar
• Logan AC, Gao H, Wang C, et al. High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment. Proc Natl Acad Sci U S A. 2011;108(52):21194–21199.
   PubMed Web of Science ®Google Scholar
• Ladetto M, Brüggemann M, Monitillo L, et al. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia. 2014;28(6):1299–1307.
   PubMed Web of Science ®Google Scholar
• Faham M, Zheng J, Moorhead M, et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood. 2012;120(26):5173–5180.
   PubMed Web of Science ®Google Scholar